Stay updated on P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.3.4, replacing Revision: v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-15T03:48:43.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    27 days ago
    Change Detected
    Summary
    Locations section added with California as a site and revision updated to v3.3.3; HHS Vulnerability Disclosure and California Locations labels were removed.
    Difference
    0.2%
    Check dated 2025-12-24T14:49:00.000Z thumbnail image
  5. Check
    50 days ago
    Change Detected
    Summary
    The only change is a revision update from v3.3.1 to v3.3.2 with no changes to study content visible. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-12-01T17:27:51.000Z thumbnail image
  6. Check
    57 days ago
    Change Detected
    Summary
    Revision: v3.3.1 added; v3.2.0 removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-24T13:48:18.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    Funding-status notice removed. The page content remains focused on the study details and locations.
    Difference
    0.4%
    Check dated 2025-11-17T06:30:13.000Z thumbnail image
  8. Check
    79 days ago
    Change Detected
    Summary
    No significant additions or deletions were detected in the page context; the study details for NCT03113487 remain intact as presented. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-03T01:11:27.000Z thumbnail image

Stay in the know with updates to P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.